pharma news

Jan 09, 2018

Key to new Cancer drugs discovered in bacterial genomes Achievement is made by the scientists of The Scripps Research Institute (TSRI) Florida campus who had previously discovered LNM E1 compound used to kill prostate cancer. This time they have unlocked the capability of LNM family molecules by “mining” the in...

Dec 19, 2017

Regeneron/Sanofi’s PD-1 drug candidate will be tested with ISA’s HPV immunotherapy Regeneron and Sanofi’s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma’s human papillomavirus (HPV) targeting drug for testing. The new drug is competing to become the sixth PD-1/PD-L1 drug on the market. Joined with...

Dec 14, 2017

Positive Phase 2 data for Roche’s lymphoma ADC Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab has already received breakthrough designation from the USFDA and priority medicine status in the EU, and the expectations for the same are running pretty high. Phase 2 data presented by the company at...

Dec 07, 2017

AbbVie aims for best-in-class psoriasis prospect The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way. AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a pha...

Nov 29, 2017

Gender matters for Party drug Ketamine to work its anti-depressant activity in mice Experiments involving the popular party drug ketamine, a psychoactive recreational drug used to uplift mood of the user, in mice has deepened the mystery of how the dug affects the brain further. Results of a study conducted at the U...

Nov 28, 2017

Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Mi...

Nov 03, 2017

AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer The exclusive collaboration for the study population allows the two companies to conduct a Phase 3 trial. Aim of this study is to evaluate patients with locally-advanced (Stage III), unresectable non-small cell lung c...

Oct 03, 2017

Strategic Immunology Alliance partners Nimbus Therapeutics and Celgene to develop therapies for Autoimmune Disorders A biotechnology company involved in the development of drugs and therapies through computational expertise announced on October 3 that they are entering into a long-term strategic alliance with Celgen...

Sep 28, 2017

Another flop for Alzeimer’s as Late Stage drug of AxovantSciences fails in trial Axovant Sciences has reported the failure of their late-stage trial involving the testing of its pill Intepirdinecould not suppress Alzheimer's symptoms in participants of the trail. The news had plunged the Wall Street into another wav...

Jul 25, 2017

Samsung and Merck launch Remicade biosim at 35% discount After the first biosimilar of Johnson & Johnson’s big-selling immunology drug Remicade hit the market last year at a modest discount, another has come along with a much deeper pricing slash. Samsung and marketing partner Merck & Co. Monday launched the...